We present a case of undifferentiated pancreatic cancer associated with humoral hypercalcemia of malignancy (HHM) in which parathyroid hormone-related protein (PTH-rP) is identified as the causative factorof hypercalcemia. A 61-year-old manwas hospitalized with right hypochondralgia. Ultrasound examination and computed tomography demonstrated a large mass in the pancreatic head with liver metastases. Biopsy of the pancreatic tumor demonstrated undifferentiated carcinoma. Serum calcium level and PTH-rP were elevated. Bone scan with technetium-99 demonstrated no accumulation inthe bones. Immunohistochemical staining for PTH-rP wasweakly positive in the tumorcells. Weconsidered that PTH-rP wasthe causative factor of HHM in thiscase from laboratory data and immunohistochemical findings. This rare case was successfully treated with pamidronate disodium, which is a type of bisphosphonate derivative. We compared this case with previously reported cases. 
INTRODUCTION
Hypercalcemia is a common complication of malignancy observedin about 10%of casesof advanced cancer. Localosteolytic hypercalcemia (LOH)is a complication of bone metastases, such as multiple myeloma, which locally release osteolytic proteins. Humoral hypercalcemia of malignancy (HHM) is a biochemical featureofcancerwithoutbonemetastases, reminiscent ofprimary hyperparathyroidism. The plasma concentration of parathyroid hormone-related protein (PTH-rP), a humoral factor having parathyroidhormone(PTH)-like bioactivity, is increased in more than 90% of patients with HHM (I ). Among the humoralfactors inducing HHM are interleukin-I, Ia,25-dihydroxyvitamin D3 and PTH. HHM is relatively common in squamous cell carcinoma of the lung and larynx (2) . In pancreatic cancer, endocrine Received April 24, 1998; accepted June 17, 1998 For reprints and all correspondence: Satoru Kakizaki, First Department of Internal Medicine, Gunma University School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511 . Japan. E-mail: kakizaki@news.sb.gunma-u.ac.jp Abbreviations: HHM, humoral hypercalcemia of malignancy; PTH-rP, parathyroid hormone-related protein; LOH, local osteolytic hypercalcemia; PTH. parathyroid hormone; Ca, calcium; BUN, blood urea nitrogen; Cr. creatinine; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; NSE, neuron specific enolase; EMA, epithelial membrane antigen; LCA, leukocyte common antigen pancreatic cancer associated with HHM is more common than exocrinepancreatic cancer. Fourteencasesof exocrinepancreatic cancerassociated with HHM have been reported (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . In only five of these cases was it confirmed that HHM was caused by PTH-rP (11) (12) (13) (14) (15) . Here, we present a case of undifferentiated pancreatic cancer associated with HHM in which PTH-rP was identified as the causativefactorof hypercalcemia. This rare case was successfully treated with pamidronate disodium, which is a type of bisphosphonate derivative. We compared this case with previously reported cases.
CASE REPORT
A 61-year-old man was hospitalized in February 1996with right hypochondralgia, whichhe first notedin December1995. He had a past history of duodenal ulcer. Ultrasound examination and computed tomography (Fig. 1 ) demonstrated a large mass in the pancreatic head with liver metastases. Biopsy of the pancreatic tumor demonstrated undifferentiated carcinoma. Initial laboratorydatawereasfollows: calcium(Ca), 11.0 mg/d1 (normal range 8.5-10.3 mg/dl); inorganic phosphorus, 2.0 mg/d1 (normalrange 2.6-4.5 mg/dl); blood urea nitrogen (BUN), 19.4mg/dl (normal range 6.0-20.0 mg/dl);creatinine(Cr), 1.0 mg/dl (normal range 0.8-1.2 mg/dl); creatinineclearance. 90.4 ml/min(normalrange 62-108 ml/min); insulin, 16 ul.l/ml (normal range 3-17 JlU/ml); gastrin, 78 pg/ml (normal range 30-140 pg/ml); glucagon 128 pg/ml (normal range 70-160 pg/mI); carcinoembryonic antigen (CEA), 1.7 ng/ml (normal <2.5 ng/ml) ; carbohydrate antigen 19-9 (CA 19-9),21 Uzml (normal <37 Uzml); and neuron specific enolase (NSE), 16.7 ng/ml (normal <10 ng/dl). Laboratory data related to Ca metabolism were as follows: high-sens itivity PTH, 87 pg/ml (normal range 15D-500 pg/ml); carboxy terminus of PTH-rP, 472.1 pmol/! (normal range 16.2-64.7 pmo1/!); calcitonin, 39 pg/ml (normal range 15-89 pg/ml); 1a,25-dihydroxyvitamin D3, 57.7 pg/ml (normal range 20-60 pg/m1); and 25-hydroxyvitamin D3. 16 ng/ml (normal range 1D-55 ng/ml) . Bone scan with technetium-99 demonstrated no accumulation in the bones. Serum Ca level was increased to 13.2 mg/dl. Thirst and loss of appetite were progressive. A 30 mg dose of parnidronate disodium by drip infusion normalized the serum Ca concentration. Although the effect of pamidronate disodium was temporary, it caused no major adverse effects and could be administered again. The patient died from the progressive cancer. A necropsy specimen of the pancreas (Fig. 2) was histologicall y identical with that of the biopsied tumor. Tumor cells had eosinophilic cytoplasm and clear nucleoli, similar to those in lymphoma. Interstitial tissue had vessels, necrosis and apoptosis. Diffuse proliferative tumor cells were loosely connected and classified as undifferentiated or anaplastic ductal carcinoma. Immunohistochemical staining for PTH-rP (16) was weakly positive in the tumor cells (Fig. 3) . We considered from laboratory data and immunohistochemical findings that PTH-rP was the causative factor of HHM in this case . Immunohistochemical staining for keratin and epithelial membrane antigen (EMA) was positive and that for leukocyte common antigen (LCA), vimentin, NSE and chromogranin was negative (not shown). These findings indicate that tumor cells were derived from epithelial cells, and a diagnosis of undifferentiated carcinoma originating from the exocrine pancreas was made.
DISCUSSION
Although the mechanism of hypercalcemia induced by a inalignant tumor without bone metastasis, so-called humoral hypercalcemia of malignancy, has long been investigated, it has not yet been clarified. Recently, PTH-rP has been shown to possess a molecular structure similar to that of native PTH which can bind to the PTH receptor in bone and kidney, mimicking some actions of PTH in order to induce hypercalcemia (17) . Standard immunoassay for PTH did not detect PTH-rP, but a specific immunoassay for PTH-rP revealed an elevation of the serum PTH-rP level in a case of islet tumor (17) .
Fourteen cases of exocrine pancreatic cancer associated with HHM have been reported (Table I) . Marked hypercalcemia in the presence ofnormal plasma concentrations ofPTH and vitamin D3 without bone metastases is compatible with HHM. Moreover, the plasma PTH-rP level was markedly elevated in this patient. Although PTH-rP is thought to be a major factor in the pathogenesis ofHHM, and PTH-rP has also been identified in the ducts and ductules of the normal pancreas (18), only five cases of exocrine pancreatic cancer with hypercalcemia due to PTH-rP have been reported (Table 2) (11-15) . HHM is common in squamous cell carcinoma, such as that of the lung and larynx (2), and is less common in pancreatic cancer. However, in pancreatic cancer, endocrine pancreatic cancer associated with HHM is Jpn J Clin OncoI1998;28 (9) 565 more common than exocrine pancreatic cancer. Only one case of undifferentiated pancreatic cancer associated with HHM in which PTH-rP was identified as the causative factor of hypercalcemia has been reported (11). Hypercalcemia in HHM is often resistant to treatment and its prognosis is very poor. Nagata (2) reported that in patients with HHM and serum Ca concentrations>12 mg/dl, 50% survived for no longer than 17 days. In our case, pamidronate disodium was effective in treating hypercalcemia. The concentration of Ca rapidly normalized. Although the effect of pamidronate disodium was temporary, it caused no major adverse effects and could be administered again.
In conclusion, we have reported a rare case of undifferentiated pancreatic cancer associated with HHM. Pamidronate disodium, a type of bisphosphonate derivative, was effective in treating HHM. It had few adverse effects and improved the quality of life in this patient.
